Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 15,834,110 | 14,884,170 | 13,482,890 | 12,400,060 | 10,836,360 |
| Cost of Goods | 2,596,405 | 2,518,334 | 2,326,752 | 2,352,880 | 2,082,540 |
| Gross Profit | 13,237,710 | 12,365,840 | 11,156,140 | 10,047,180 | 8,753,810 |
| Operating Expenses | 7,088,186 | 6,757,271 | 6,063,785 | 5,866,350 | 5,386,080 |
| Operating Income | 6,149,924 | 5,608,903 | 5,093,107 | 4,181,710 | 3,368,280 |
| Interest Expense | 100,383 | 116,834 | 308,966 | 0 | 0 |
| Other Income | 29,776 | 303,127 | 21,600 | -83,930 | -107,890 |
| Pre-tax Income | 6,079,317 | 5,795,196 | 4,805,741 | 4,097,780 | 3,260,390 |
| Income Tax | 1,357,755 | 1,309,926 | 1,102,291 | 902,350 | 692,330 |
| Net Income Continuous | 4,721,563 | 4,485,271 | 3,703,449 | 3,030,153 | 2,659,946 |
| Net Income | $4,721,563 | $4,485,271 | $3,703,449 | $3,195,420 | $2,568,050 |
| EPS Basic Total Ops | 0.90 | 0.84 | 0.68 | 0.54 | 0.45 |
| EPS Basic Continuous Ops | 0.90 | 0.84 | 0.68 | 0.54 | 0.45 |
| EPS Diluted Total Ops | 0.90 | 0.83 | 0.67 | 0.53 | 0.45 |
| EPS Diluted Continuous Ops | 0.90 | 0.83 | 0.67 | 0.53 | 0.45 |
| EBITDA(a) | $6,762,384 | $6,107,404 | $5,558,458 | $4,181,710 | $3,808,140 |